



	Dr. Vinay Cho MD (Pathology & M Chairman & Consu	1icrobiology)	M	m Chopra D (Pathology) nt Pathologist					
NAME	: Mr. DAVENDER KUMAR								
AGE/ GENDER	: 48 YRS/MALE		PATIENT ID	: 1816180					
COLLECTED BY			REG. NO./LAB NO.	: 012504030001					
REFERRED BY			REGISTRATION DATE	: 03/Apr/2025 07:1	0 AM				
				1					
BARCODE NO.	: 01528257		COLLECTION DATE	: 03/Apr/2025 07:19					
CLIENT CODE.	: KOS DIAGNOSTIC LAB		REPORTING DATE	:03/Apr/2025 12:3	oPM				
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	MBALA CANTT							
Test Name		Value	Unit	Biological	Reference interval				
		HAEMA	TOLOGY						
	GLYCO	SYLATED HA	AEMOGLOBIN (HB.	A1C)					
GLYCOSYLATED HAEMOGLOBIN (HbA1c): WHOLE BLOOD		11.4 ^H	%	4.0 - 6.4					
by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY) ESTIMATED AVERAGE PLASMA GLUCOSE by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)		280.48 ^H	mg/dL	60.00 - 140	0.00				
INTERPRETATION:									
	AS PER AMERICAN D								
	REFERENCE GROUP	GL	GLYCOSYLATED HEMOGLOGIB (HBAIC) in %						
	Non diabetic Adults >= 18 years		<5.7						
	At Risk (Prediabetes)		5.7 - 6.4						
D	iagnosing Diabetes		>= 6.5						
	iagnosing Diabetes	Cools	Age > 19 Years						
			Age > 19 Years of Therapy:	< 7.0					
	iagnosing Diabetes ic goals for glycemic control		Age > 19 Years	< 7.0 >8.0					

KOS Diagnostic Lab

(A Unit of KOS Healthcare)

1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients. 2.Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.

3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be appropriate.

4. High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.

6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.

7.Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT



TEST PERFORMED AT KOS DIAGNOSTIC LAB, AMBALA CANTT.



KOS Diagnostic Lab (A Unit of KOS Healthcare)

	Dr. Vinay Chopra MD (Pathology & Microbiology) Chairman & Consultant Pathologist		Dr. Yugam Chopra MD (Pathology) CEO & Consultant Pathologist	
NAME	: Mr. DAVENDER KUMAR			
AGE/ GENDER	: 48 YRS/MALE	PAT	FIENT ID	: 1816180
COLLECTED BY	:	REG	G. NO./LAB NO.	: 012504030001
REFERRED BY	:	REG	GISTRATION DATE	: 03/Apr/2025 07:10 AM
BARCODE NO.	:01528257	COL	LECTION DATE	:03/Apr/202507:19AM
CLIENT CODE.	: KOS DIAGNOSTIC LAB	RE	PORTING DATE	: 03/Apr/2025 11:31AM
CLIENT ADDRESS	: 6349/1, NICHOLSON ROAD, A	MBALA CANTT		
Test Name		Value	Unit	Biological Reference interval
	CLINICA	L CHEMISTR	RY/BIOCHEMIS	STRY
		GLUCOSE FA	STING (F)	
GLUCOSE FASTIN by GLUCOSE OXIDAS	G (F): PLASMA E - PEROXIDASE (GOD-POD)	198.45 ^H	mg/dL	NORMAL: < 100.0 PREDIABETIC: 100.0 - 125.0 DIABETIC: > 0R = 126.0
	* '	** End Of Repo	rt ***	
		A.	ha	
	am	the		

DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

Ě,

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS , MD (PATHOLOGY)

